Information from Industry - Sponsored Supplement

A Clinical Review of Eslicarbazepine Acetate

This supplement is supported by an independent medical education grant from Sunovion Pharmaceuticals, Inc.


When managing seizures, physicians have multiple treatment choices developed over the past half century. Partial-onset seizures, or focal seizures, represent the majority of cases. Neurologists and primary care providers are tasked with choosing the first-, second-, or third-line option for monotherapy, and determining when treatment-refractory cases require adjunct treatment. 

This supplement reviews Eslicarbazepine Acetate and its effectiveness as a first-line or later adjunctive therapy in patients with partial-onset seizures.

Click here to read more

Next Article: